Coronavirus Coverage
The PRWeekly: Managing COVID-19 and the 'Pingdemic' | Ditch the pitch | Tokyo Olympics
PRWeek's podcast takes listeners behind the headlines of the week's most important news, views and industry gossip.
The Vaccine Project Newsletter: Delta dawns a new day of masks and mandates
This week's edition of the Vaccine Project Newsletter is 2,742 words and will take eight minutes to read.
Brands must fight harder for coverage as media output shrinks, new research finds
The InformationA report on the UK’s changing media landscape and its impact on brand communication reveals how brands are having to fight harder than ever for coverage and engage with ‘big issues’ such as social purpose and sustainability.
From the Editor in Chief: 'PR bosses are now facing a looming staff crisis as a result of the pandemic'
The KnowledgeAsk most PR bosses about their most pressing professional concern now we are in the second half of this challenging year, and they’ll give you an immediate answer: “My staff.”
Three days a week? Every day? Never? Agencies tread lightly on bringing staff back to office
Most employees want RTO flexibility and some don’t want to come back at all. How agencies are preparing for the backlash.
The PR Week: 7.22.2021: Andy Wilson, DrivePath Advisors
Wilson talks about founding an agency, C-suite communications and more.
The Vaccine Project Newsletter: A midsummer nightmare?
This week’s Vaccine Project Newsletter is 2,650 words and will take you eight minutes to read.
Nightclub revellers to cautious jet-setters – communicating 'Freedom Day'
The ending of nearly all England's COVID-19 restrictions on Monday required substantial PR efforts for companies and others directly affected. We speak to four organisations about how they navigated the tricky comms challenges of 'Freedom Day'.
The Vaccine Project Newsletter: The vaccine push, and the pushback
This week’s Vaccine Project Newsletter is 2,768 words and will take you seven minutes to read.
The PR Week: 7.13.2021: Sally Susman, Pfizer
Susman talks about leading the comms around coronavirus vaccines, the evolution of the pharma industry's reputation and more.